Alembic Pharmaceuticals Limited
NSE: APLLTD BSE: APLLTD
NSE
880.55
-3.25 (-0.37%)
Prev Close
883.8
Open Price
884.9
Volume
310,579
Today Low / High
875.65 / 918.65
52 WK Low / High
725.2 / 1303.9
Range
837 - 925
BSE
881.45
-1.70 (-0.19%)
Prev Close
883.15
Open Price
883.85
Volume
4,042
Today Low / High
878.4 / 918.65
52 WK Low / High
725.6 / 1296.15
Range
837 - 926
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 880.55 (target range: 837 - 925), reflecting a change of -3.25 (-0.36773%). On the BSE, it is listed at 881.45 (target range: 837 - 926), showing a change of -1.7 (-0.19249%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
24 Apr
884.90
-0.49%
23 Apr
859.80
2.79%
22 Apr
855.80
0.00%
21 Apr
856.00
-0.74%
17 Apr
846.60
0.39%
16 Apr
847.00
0.58%
15 Apr
853.95
-0.88%
11 Apr
848.00
-0.19%
09 Apr
856.35
-1.87%
08 Apr
859.05
-1.18%
07 Apr
775.50
8.96%
04 Apr
894.95
-1.53%
03 Apr
898.25
-1.24%
02 Apr
904.80
-2.19%
01 Apr
921.95
-2.72%
28 Mar
937.25
-0.80%
27 Mar
902.85
3.15%
Alembic Pharmaceuticals Limited Graph
Alembic Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 880.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 881.45 | 890.26 | 801.24 - 979.29 |
| 899.08 | 719.26 - 1,078.89 | ||
| 907.89 | 635.53 - 1,180.26 | ||
| Bearish Scenario | 881.45 | 872.64 | 785.37 - 959.90 |
| 863.82 | 691.06 - 1,036.59 | ||
| 855.01 | 598.50 - 1,111.51 |
Overview of Alembic Pharmaceuticals Limited
ISIN
INE901L01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
223,086
Market Cap
173,083,664,122
Last Dividend
11
Official Website
IPO Date
2011-09-20
DCF Diff
313.19
DCF
567
Financial Ratios Every Investor Needs
Stock Dividend of APLLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-15 | July 15, 24 | 11 | 11 | 2024-07-15 | 2024-08-21 | |
| 2023-07-28 | July 28, 23 | 8 | 8 | 2023-07-28 | 2023-09-03 | |
| 2022-08-17 | August 17, 22 | 10 | 10 | 2022-08-18 | 2022-09-03 | |
| 2021-07-19 | July 19, 21 | 14 | 14 | 2021-07-20 | 2021-07-31 | |
| 2020-03-16 | March 16, 20 | 7 | 7 | 2020-03-17 | 2020-04-05 | 2020-03-06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 6,228.63 Cr | 3,959.80 Cr | 2,268.83 Cr | 0.3643 | 438.56 Cr | 251.97 Cr | 575.81 Cr | 615.82 Cr | 31.33 | 961.67 Cr | 0.0989 |
| 2023-03-31 | 5,652.62 Cr | 1,708.82 Cr | 3,943.80 Cr | 0.6977 | 29.07 Cr | 241.05 Cr | 437.78 Cr | 341.99 Cr | 17.40 | 711.11 Cr | 0.0605 |
| 2022-03-31 | 5,231.79 Cr | 1,723.19 Cr | 3,508.60 Cr | 0.6706 | 50.59 Cr | 210.98 Cr | 587.47 Cr | 520.94 Cr | 26.50 | 924.62 Cr | 0.0996 |
| 2021-03-31 | 5,276.22 Cr | 1,521.27 Cr | 3,754.95 Cr | 0.7117 | 25.38 Cr | 208.66 Cr | 1,296.84 Cr | 1,146.50 Cr | 59.18 | 1,567.57 Cr | 0.2173 |
| 2020-03-31 | 4,491.97 Cr | 1,314.11 Cr | 3,177.86 Cr | 0.7075 | 42.64 Cr | 155.12 Cr | 1,111.41 Cr | 828.82 Cr | 43.97 | 1,184.30 Cr | 0.1845 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 120.21 Cr | 6,445.58 Cr | 1,627.38 Cr | 4,818.2000 Cr | 513.16 Cr | 392.95 Cr | 1,643.54 Cr | 3,071.05 Cr | 0.00 Cr | 0.00 Cr | 93.02 Cr | 1,455.0000 Cr |
| 2023-03-31 | 75.48 Cr | 6,182.83 Cr | 1,812.36 Cr | 4,370.4700 Cr | 722.02 Cr | 646.54 Cr | 1,475.27 Cr | 2,999.73 Cr | 218.79 Cr | -83.14 Cr | 96.33 Cr | 1,636.9300 Cr |
| 2022-03-31 | 61.09 Cr | 7,122.03 Cr | 1,884.48 Cr | 5,237.5500 Cr | 717.11 Cr | 656.02 Cr | 1,609.70 Cr | 3,947.26 Cr | 365.18 Cr | -197.69 Cr | 118.40 Cr | 1,716.5300 Cr |
| 2021-03-31 | 98.06 Cr | 6,708.98 Cr | 1,642.01 Cr | 5,127.6100 Cr | 583.61 Cr | 485.55 Cr | 1,486.15 Cr | 3,648.03 Cr | 299.87 Cr | 85.52 Cr | 49.31 Cr | 1,280.8400 Cr |
| 2020-03-31 | 71.84 Cr | 5,989.05 Cr | 2,798.60 Cr | 3,219.4100 Cr | 1,830.69 Cr | 1,758.85 Cr | 1,187.53 Cr | 3,099.01 Cr | 213.38 Cr | 74.51 Cr | 17.62 Cr | 1,751.6000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 803.2000 Cr | -320.6100 Cr | -437.8700 Cr | 475.7300 Cr | 44.7300 Cr | 120.2100 Cr | -327.4700 Cr | 615.8200 Cr | -205.4100 Cr | -157.2500 Cr | -168.2800 Cr |
| 2023-03-31 | 723.9500 Cr | -447.5900 Cr | -261.9600 Cr | 280.5400 Cr | 14.3900 Cr | 75.4800 Cr | -443.4100 Cr | 354.5900 Cr | 5.8700 Cr | -196.5600 Cr | 134.4400 Cr |
| 2022-03-31 | 552.3500 Cr | -371.9700 Cr | -217.3500 Cr | 126.7100 Cr | -36.9700 Cr | 61.0900 Cr | -425.6400 Cr | 620.1100 Cr | 129.9800 Cr | -275.1900 Cr | -123.5500 Cr |
| 2021-03-31 | 1,463.3800 Cr | -838.8100 Cr | -597.4300 Cr | 803.8700 Cr | 26.2200 Cr | 98.0600 Cr | -659.5100 Cr | 1,368.0800 Cr | -397.9900 Cr | 0.0000 Cr | -298.6200 Cr |
| 2020-03-31 | 449.1300 Cr | -731.6300 Cr | 154.8500 Cr | -285.7700 Cr | -127.2300 Cr | 71.8400 Cr | -734.9000 Cr | 999.8200 Cr | 160.5300 Cr | -325.9700 Cr | -220.2700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,692.74 Cr | 439.54 Cr | 1,253.20 Cr | 0.7403 | 190.18 Cr | 138.42 Cr | 7.01 | 270.08 Cr | 0.0818 |
| 2024-09-30 | 1,647.98 Cr | 429.12 Cr | 1,218.86 Cr | 0.7396 | 168.75 Cr | 153.41 Cr | 7.79 | 269.74 Cr | 0.0931 |
| 2024-06-30 | 1,561.73 Cr | 842.90 Cr | 718.83 Cr | 0.4603 | 167.79 Cr | 134.71 Cr | 6.84 | 238.93 Cr | 0.0863 |
| 2024-03-31 | 1,516.98 Cr | 850.70 Cr | 666.28 Cr | 0.4392 | 190.58 Cr | 178.21 Cr | 9.07 | 263.66 Cr | 0.1175 |
| 2023-12-31 | 1,630.57 Cr | 460.76 Cr | 1,169.81 Cr | 0.7174 | 199.75 Cr | 180.45 Cr | 9.18 | 269.26 Cr | 0.1107 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 122.05 Cr | 27.22 Cr | 149.27 Cr | 0.00 Cr | 2,012.52 Cr | 3,762.39 Cr | 3,124.86 Cr | 7,230.25 Cr | 2,342.61 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | -4,818.20 Cr |
| 2024-03-31 | 126.57 Cr | 27.13 Cr | 126.57 Cr | 1,024.84 Cr | 1,643.54 Cr | 3,078.56 Cr | 3,071.07 Cr | 6,445.58 Cr | 1,627.38 Cr |
| 2023-12-31 | -147.80 Cr | 295.60 Cr | 147.80 Cr | 0.00 Cr | 0.00 Cr | 147.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 141.30 Cr | 17.22 Cr | 158.52 Cr | 1,075.07 Cr | 1,539.24 Cr | 3,134.13 Cr | 3,080.82 Cr | 6,455.27 Cr | 1,985.26 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 134.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 178.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 180.45 Cr | 138.90 Cr | 0.00 Cr | 0.00 Cr | 138.90 Cr | 286.70 Cr | 147.80 Cr | 0.00 Cr | 138.90 Cr |
| 2023-09-30 | 136.56 Cr | 135.12 Cr | 0.00 Cr | 0.00 Cr | 135.12 Cr | 147.80 Cr | 12.68 Cr | 0.00 Cr | 135.12 Cr |
| 2023-06-30 | 120.60 Cr | 132.36 Cr | 0.00 Cr | 0.00 Cr | 132.36 Cr | 214.63 Cr | 82.27 Cr | 0.00 Cr | 132.36 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,803.90 | ₹4,328,061,192,000.00 | ₹2,100,537.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,215.50 | ₹1,650,019,896,835.00 | ₹2,081,003.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,325.10 | ₹1,125,363,469,500.00 | ₹233,320.00 |
| Mankind Pharma Limited | MANKIND | ₹2,599.20 | ₹1,072,374,089,184.00 | ₹377,773.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,200.50 | ₹1,000,152,180,510.00 | ₹4,818,144.00 |
| Lupin Limited | LUPIN | ₹2,104.10 | ₹960,658,479,623.00 | ₹1,580,050.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹880.25 | ₹885,733,957,500.00 | ₹1,164,194.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,257.80 | ₹730,532,755,600.00 | ₹1,338,274.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,201.20 | ₹621,881,478,000.00 | ₹138,164.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,420.90 | ₹400,960,929,200.00 | ₹1,391,085.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,445.70 | ₹366,779,872,800.00 | ₹175,209.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,790.40 | ₹348,554,444,800.00 | ₹239,346.00 |
| Laurus Labs Limited | LAURUSLABS | ₹645.50 | ₹348,087,811,500.00 | ₹7,230,008.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,204.80 | ₹306,699,912,000.00 | ₹269,079.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,609.10 | ₹250,500,214,702.00 | ₹175,168.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,465.20 | ₹238,064,230,800.00 | ₹1,148,314.00 |
| Piramal Enterprises Limited | PEL | ₹1,021.60 | ₹230,348,324,800.00 | ₹349,675.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,967.50 | ₹224,187,500,000.00 | ₹18,935.00 |
| Eris Lifesciences Limited | ERIS | ₹1,512.00 | ₹205,827,048,000.00 | ₹433,227.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹880.55 | ₹173,083,664,122.00 | ₹310,579.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,079.00 | ₹167,802,262,100.00 | ₹52,920.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹902.85 | ₹161,709,463,500.00 | ₹16,724,971.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹952.65 | ₹151,739,178,021.00 | ₹684,427.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,884.40 | ₹143,236,447,480.00 | ₹153,894.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹475.05 | ₹115,220,527,200.00 | ₹1,362,207.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,221.50 | ₹86,673,767,100.00 | ₹4,879.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹721.80 | ₹70,585,471,620.00 | ₹517,725.00 |
| FDC Limited | FDC | ₹426.15 | ₹69,381,481,500.00 | ₹253,775.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹753.90 | ₹68,329,440,018.00 | ₹548,769.00 |
| Strides Pharma Science Limited | STAR | ₹681.05 | ₹62,767,406,835.00 | ₹639,460.00 |
| Innova Captab Limited | INNOVACAP | ₹910.95 | ₹52,129,049,984.00 | ₹78,436.00 |
| Hikal Limited | HIKAL | ₹416.75 | ₹51,385,691,750.00 | ₹273,356.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹154.99 | ₹50,297,664,780.00 | ₹933,378.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹640.35 | ₹45,084,354,030.00 | ₹43,561.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹843.50 | ₹42,781,560,850.00 | ₹107,819.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,333.40 | ₹38,592,102,600.00 | ₹15,218.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹384.50 | ₹38,556,891,000.00 | ₹372,674.00 |
| Sequent Scientific Limited | SEQUENT | ₹154.04 | ₹38,556,520,080.00 | ₹1,239,540.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹62.22 | ₹34,093,697,880.00 | ₹39,557,174.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹365.85 | ₹33,391,129,500.00 | ₹235,772.00 |
| Suven Life Sciences Limited | SUVEN | ₹141.20 | ₹30,792,048,800.00 | ₹1,492,336.00 |
| Alembic Limited | ALEMBICLTD | ₹106.25 | ₹27,283,087,394.00 | ₹492,387.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹534.15 | ₹25,667,509,950.00 | ₹126,098.00 |
Key Executives
Director of Finance, Chief Financial Officer & Executive Director
Mr. Raj Kumar Shreeram Baheti B.Com.(Hon.), FCA, FCS
Gender: male
Year Born: 1959
Chief Scientific Officer
Dr. J. Venkat Raman M. S., Ph.D.
Gender: Not Specified
Year Born: 1958
Senior Vice President of Finance
Mr. Ajay Kumar Desai
Gender: male
Year Born:
Company Secretary & Compliance Officer
Ms. Manisha Saraf
Gender: female
Year Born:
Managing Director
Mr. Pranav Chirayu Amin
Gender: male
Year Born: 1975
Chief Business Development Officer
Mr. Udit C. Amin
Gender: male
Year Born: 1980
MD & Executive Director
Mr. Shaunak Chirayu Amin
Gender: male
Year Born: 1978
Senior Vice President
Mr. Gautam Chatterjee
Gender: male
Year Born: 1961
Head of Technical Operations
Mr. Sudhakar Pandiyan
Gender: male
Year Born:
Executive Chairman & Chief Executive Officer
Mr. Chirayu Ramanbhai Amin
Gender: male
Year Born: 1946
FAQs about Alembic Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mr. Chirayu Ramanbhai Amin.
What is the current market price of the stock?
The current price is ₹880.55.
What is the 52-week price range?
The range is ₹725.2-1303.9.
What is the market capitalization of the company?
The market capitalization is ₹17,308.37 crores.
What is the dividend yield?
The dividend yield is 1.25%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 28.75.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Pharmaceuticals Limited (ISIN: INE901L01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹17,308.37 crores and an average daily volume of 223,086 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.